Zentalis Pharmaceuticals, Inc. (ZNTL)
NASDAQ: ZNTL · Real-Time Price · USD
3.000
+0.070 (2.39%)
Dec 20, 2024, 4:00 PM EST - Market closed
Zentalis Pharmaceuticals Revenue
Zentalis Pharmaceuticals had revenue of $40.56M in the twelve months ending September 30, 2024.
Revenue (ttm)
$40.56M
Revenue Growth
n/a
P/S Ratio
5.25
Revenue / Employee
$327,097
Employees
124
Market Cap
213.80M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
biote | 193.06M |
LifeMD | 193.06M |
ADC Therapeutics | 70.72M |
SOPHiA GENETICS | 64.49M |
Utah Medical Products | 44.08M |
Precigen | 3.96M |
Inhibikase Therapeutics | 1.00 |
ZNTL News
- 9 days ago - Zentalis Pharmaceuticals Announces Key Management Appointments - GlobeNewsWire
- 19 days ago - Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm - GlobeNewsWire
- 2 months ago - FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc - GuruFocus
- 3 months ago - FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers - Benzinga
- 3 months ago - Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies - GlobeNewsWire
- 3 months ago - Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024 - GlobeNewsWire
- 4 months ago - Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL - Business Wire